Voyageur Pharmaceuticals Ltd. (TSX-V: VM) announced that independent laboratory testing confirmed pharmaceutical-grade purity for its barium sulfate active pharmaceutical ingredient sourced from the Frances Creek barite property in British Columbia. Results showed an average purity of 98.8% BaSO4, exceeding the USP monograph requirement of 97.5%, with multiple batches achieving 99.1% to 99.4% purity. All samples passed full USP monograph tests, including identification, pH, loss on drying, limit of soluble barium salts, acid-soluble substances, sulfides, and microbiological requirements. Elemental impurities testing showed heavy metal levels significantly lower than specifications.
The processed barite achieved 1-micron and 10-micron particle sizes, with d50 values of 1.1-1.9 µm and d90 values as low as 2.5 µm under optimal conditions. Micronized samples met USP particle size and performance criteria, exhibited good flowability, 100% yield, and no discoloration. The acid-wash procedure and final processing were conducted in a cGMP-compliant environment at SGS Laboratories in Mississauga, Ontario.
With this milestone, Voyageur advances to stage two of the Alberta Innovates AICE-Market Access Program. The upcoming clinical trial will compare Voyageur's barium contrast agents with current standard-of-care options for gastrointestinal computed tomography and fluoroscopic imaging. CEO Brent Willis stated, "These results represent a major de-risking milestone. The upcoming clinical trial in patients is the final bridge to using our Frances Creek API in our Health Canada-approved contrast products."
The clinical trial, designed by Chief Scientific Officer Dr. Iryna Saranchova in accordance with Health Canada standards, will evaluate investigational agents against both barium-based and iodinated oral contrasts. Successful outcomes are expected to validate clinical performance, strengthen regulatory positioning, and accelerate market adoption. Full study completion is targeted for the fourth quarter of 2026. Results will also support FDA licensing applications beginning in the first quarter of 2026 and contribute to the prefeasibility and final feasibility study for the Frances Creek project, expected by the fourth quarter of 2026.
By developing this domestic resource, Voyageur is building a fully integrated supply chain from quarry to finished contrast media, reducing reliance on imported or synthetic materials. The company also announced the grant of 378,651 Deferred Share Units to directors and a consultant, and 4,300,000 stock options to directors and officers, along with options for a contractor. Additionally, Voyageur intends to issue units for debt to an arm's length third party at a deemed value of $100,000, subject to TSX Venture Exchange approval. More information is available on the company's website: https://voyageurpharmaceuticals.ca.
